1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,338 | 0,342 | 02.10. | |
| 0,329 | 0,350 | 02.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
| Do | Cosmos Health Inc.: Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion | 418 | ACCESS Newswire | More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded genericsProprietary... ► Artikel lesen | |
| Di | Cosmos Health's CosmoFarm unit reaches $15M quarterly revenue | 4 | Investing.com | ||
| Di | CosmoFarm: Tochtergesellschaft von Cosmos Health erreicht Quartalsumsatz von 15 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| Di | Cosmos Health Inc.: Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue | 600 | ACCESS Newswire | Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarmRevenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal... ► Artikel lesen | |
| Mo | Cosmos Health climbs as CMO pipeline surpasses $20M in implied revenue | 3 | Seeking Alpha | ||
| Mo | Cosmos Health's Cana unit surpasses $20M CMO pipeline | 4 | Investing.com | ||
| Mo | Cosmos Health Inc.: Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline | 237 | ACCESS Newswire | Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreementsGross... ► Artikel lesen | |
| 15.09. | Cosmos Health subsidiary secures 5.2M unit manufacturing deal | 8 | Investing.com | ||
| 15.09. | Cosmos Health Inc.: Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June | 464 | ACCESS Newswire | 7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million todaySecured orders for 1.04 million... ► Artikel lesen | |
| 14.09. | Cosmos Health Inc.: Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market | 563 | ACCESS Newswire | Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stockPositions Cosmos Health... ► Artikel lesen | |
| 11.09. | Cosmos Health Tochter sichert sich Fünfjahres-Produktionsvertrag | 1 | Investing.com Deutsch | ||
| 11.09. | Cosmos Health subsidiary secures 5-year manufacturing deal | 2 | Investing.com | ||
| 11.09. | Cosmos Health Inc.: Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units | 518 | ACCESS Newswire | 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana LaboratoriesExpands Cosmos Health's manufacturing presence... ► Artikel lesen | |
| 09.09. | Cosmos Health Inc.: Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market | 1.669 | ACCESS Newswire | First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVetFormulated for dogs, cats, horses, companion and large animals, and supplied... ► Artikel lesen | |
| 03.09. | Cosmos Health reports record revenue, retires $8M debt early | 4 | Investing.com | ||
| 03.09. | Cosmos Health Inc.: A Company Transformed - 2026 Year-to-Date | 322 | GlobeNewswire (Europe) | A Comprehensive Corporate Summary - January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) ? Q1 2026 $17.93M (+31%) ? Q2 2026 $18.99M (+28.8%) ?... ► Artikel lesen | |
| 28.08. | Cosmos Health Inc.: Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions | 575 | GlobeNewswire (Europe) | $8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilutionSimplified capital structure... ► Artikel lesen | |
| 24.08. | Cosmos Health projects $6M revenue from Oliv18 supplement launch | 1 | Investing.com | ||
| 24.08. | Cosmos Health: Neues Nahrungsergänzungsmittel Oliv18 soll 6 Millionen US-Dollar Umsatz generieren | - | Investing.com Deutsch | ||
| 24.08. | Cosmos Health Inc.: Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18 Across the U.S. Cardiovascular Health and Antioxidant Categories | 394 | GlobeNewswire (Europe) | CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting... ► Artikel lesen |
1 2 3 4 5 Weiter >>
187 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Biosimilars: Stada: Pembrolizumab aus China | ||
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 34,600 | -1,14 % | XFRA TEVA: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVA PHARMACEUT.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| ABBOTT LABORATORIES | 86,72 | +0,14 % | Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday | ||
| INNOCAN PHARMA | 1,265 | -0,78 % | Innocan Pharma Corporation: VALITIC Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA | HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer... ► Artikel lesen | |
| MPH HEALTH CARE | 27,700 | +0,36 % | MPH Health Care: 5-Euro-Dividende - das wird übersehen |
Das Unternehmen COSMOS HEALTH INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,41 %) liegt der Kurs bei 0,338 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COSMOS HEALTH INC finden Sie auf Wallstreet Online.